Invesco NASDAQ Biotech UCITS ETF Acc
IE00BQ70R696
Invesco NASDAQ Biotech UCITS ETF Acc/ IE00BQ70R696 /
NAV06/06/2024 |
Diferencia-0.1869 |
Tipo de beneficio |
Enfoque de la inversión |
Sociedad de fondos |
46.8507USD |
-0.40% |
reinvestment |
Equity
ETF Stocks
|
Invesco IM ▶ |
Estrategia de inversión
The objective of the Fund is to aim to track the Total Return performance of the NASDAQ Biotechnology Index (the "Index"), less fees, expenses and transaction costs. The Fund"s base currency is USD. The Index is designed to represent the performance of biotechnology and pharmaceutical securities on the NASDAQ Stock Market. The Index is a modified market capitalisation weighted index. The securities eligible for inclusion include common stocks, ordinary shares, ADRs and shares of beneficial interest or limited partnership interests. The Index has approximately 116 components and is rebalanced on a quarterly basis. Investors should note that the Index is the intellectual property of the index provider.
The Fund is a passively managed Exchange-Traded Fund. To achieve the objective the Fund will use unfunded swaps ("Swaps"). These Swaps are an agreement between the Fund and an approved counterparty to exchange one stream of cash flows against another stream but do not require the Fund to provide collateral, on the basis that the Fund has already invested in a basket of equities and equity related securities (namely shares). Please note that the Fund will purchase securities that are not contained in the Index. The performance of the Index is swapped from the counterparty to the Fund in exchange for the performance of equities and equity related securities held by the Fund.
Objetivo de inversión
The objective of the Fund is to aim to track the Total Return performance of the NASDAQ Biotechnology Index (the "Index"), less fees, expenses and transaction costs. The Fund"s base currency is USD. The Index is designed to represent the performance of biotechnology and pharmaceutical securities on the NASDAQ Stock Market. The Index is a modified market capitalisation weighted index. The securities eligible for inclusion include common stocks, ordinary shares, ADRs and shares of beneficial interest or limited partnership interests. The Index has approximately 116 components and is rebalanced on a quarterly basis. Investors should note that the Index is the intellectual property of the index provider.
Datos maestros
Tipo de beneficio: |
reinvestment |
Categoría de fondos: |
Equity |
País: |
United States of America |
Sucursal: |
ETF Stocks |
Punto de referencia: |
NASDAQ Biotechnology Index Total Return |
Inicio del año fiscal: |
01/12 |
Última distribución: |
- |
Banco depositario: |
Northern Trust Fiduciary Services |
País de origen: |
Ireland |
Permiso de distribución: |
Austria, Germany, Switzerland |
Gestor de fondo: |
Assenagon Asset Management S.A. |
Volumen de fondo: |
344.82 millones
USD
|
Fecha de fundación: |
07/11/2014 |
Enfoque de la inversión: |
- |
Condiciones
Recargo de emisión: |
0.00% |
Max. Comisión de administración: |
0.40% |
Inversión mínima: |
1.00 USD |
Deposit fees: |
- |
Cargo por amortización: |
0.00% |
Prospecto simplificado: |
Descargar (Versión para imprimir) |
Activos
Stocks |
|
98.92% |
Otros |
|
1.08% |
Países
United States of America |
|
80.71% |
Switzerland |
|
2.97% |
Israel |
|
2.92% |
Sweden |
|
2.65% |
China |
|
2.42% |
Argentina |
|
1.29% |
Ireland |
|
1.24% |
Denmark |
|
1.20% |
Canada |
|
0.94% |
Germany |
|
0.92% |
Netherlands |
|
0.69% |
Bermuda |
|
0.46% |
Finland |
|
0.40% |
Norway |
|
0.10% |
Otros |
|
1.09% |
Sucursales
Consumer goods |
|
25.54% |
IT/Telecommunication |
|
20.26% |
Healthcare |
|
18.15% |
Industry |
|
11.86% |
Finance |
|
10.53% |
Energy |
|
6.95% |
Utilities |
|
3.32% |
Commodities |
|
2.26% |
Otros |
|
1.13% |